Impax

Impax wins final FDA approval for generic depression drug

Dec 01, 2008 (Datamonitor via COMTEX) -- -- Impax Laboratories, a specialty pharmaceutical company, has announced that the FDA has granted final approval of the company's abbreviated new drug application for a generic version...

RPT-PREVIEW-UK climate change body to unveil emissions cut plans

By Peter Griffiths LONDON, Nov 28 (Reuters) - British Prime Minister Gordon Brown set up the committee to advise ministers on what his government describes as the world's greatest environmental challenge. Energy and Climate...

Consumer Electronics and Casual Apparel Are Top Ticket Items on Black Friday

NearbyNow Reports Product Demand Information for Hundreds of Local Shopping Areas Across the US for First Official 2008 Holiday Shopping Weekend MOUNTAIN VIEW, CA--(Marketwire - Black Friday and the following Saturday showed...

Sun loses $3-bn revenue potential from US

Osmotica pips Indian firm to get FDA nod for selling anti-depressant. Sun Pharmaceutical Industries, India's largest drug maker by market value, has lost out on a $3-billion revenue potential from the US market after a rival...

IMPAX Receives Final FDA Approval For Generic Wellbutrin(R) XL 150 Mg

IMPAX Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) granted final approval of the Company's Abbreviated New Drug Application (ANDA) for a generic version of Wellbutrin® XL 150 mg Extended-release...

Health Cost Containment Index: Expanding Into India, Impax Labs Set to Re-List

The ETF Innovators (ETFI) Global Healthcare Cost Containment Index profiled in the accompanying table is updated and expanded to include more companies from my recent Analysis of Generic Drug Companies from India. The index is...

Agfa HealthCare to display IMPAX™ Data Center at RSNA 2008

Leading vendor neutral image infrastructure solution consolidates data from disparate systems into a single point of storage - - (RSNA Booth #4800) Agfa HealthCare, a leading provider of IT-enabled cli... [WebWire - Monday,...

UPDATE 1-MOVES-KKR, Citigroup, Evolution Securities, Impax

KOHLBERG KRAVIS ROBERTS&CO (KKR) Citigroup's South Asia Chief Executive Sanjay Nayar has quit to run private-equity firm Kohlberg Kravis Roberts&Co's new Indian unit, leaving the struggling bank after a 23-year career. Nayar...

UPDATE - MOVES-KKR, Citigroup, Evolution Securities, Impax (at Reuters)

KOHLBERG KRAVIS ROBERTS & CO (KKR) [KKR.UL] ) South Asia Chief Executive Sanjay Nayar has quit to run private-equity firm Kohlberg Kravis Roberts & Co's new Indian unit, leaving the struggling bank after a 23-year career. Nayar...

Lilly sues generic drug makers over Cymbalta

Pharmaceutical company Eli Lilly is suing generic drug companies for infringing its patents for the anti-depressant drug Cymbalta (duloxetine). Lilly filed suit against Impax Laboratories, Cobalt Laboratories, Wockhardt and...

1 2 next